Navitoclax + Rux study VAF and Fibrosis for MF

[EPguy]

This may already be posted, but I can't find it.

Navitoclax study looks promising for Rux resistant MF.

-One novel item of interest is an actual correlation between survival and VAF (allele burden) and/or fibrosis grade reductions with this agent:

<<"What is most notable in this analysis is the overall survival among patients who demonstrate VAF and BMF responses >>

<<VAF and BMF responses occurred despite the presence of high molecular risk mutations>>

VAF reduction of more than 20% (23% of patients) and fibrosis of at least 1 grade (38% of patients) provided the benefit.

Reductions were measured at week 24, I assume they will continue the study.

It is a dose finding study and there were a lot of AE's, so they are adjusting doses.

news.abbvie.com/news/press-...

[Meatloaf9]

Thank you for posting. Another positive move forward.